Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

A multi-center randomized, controlled, open-label trial evaluating the effects of eosinophil-guided corticosteroid-sparing therapy in hospitalised patients with COPD exacerbations - The CORTICO steroid reduction in COPD (CORTICO-COP) study protocol

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Do-not-resuscitate orders in patients with community-acquired pneumonia: a retrospective study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Increased respiratory morbidity in individuals with interstitial lung abnormalities

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Validation of the King's Brief Interstitial Lung Disease questionnaire in Idiopathic Pulmonary Fibrosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Lower mortality after early supervised pulmonary rehabilitation following COPD-exacerbations: a systematic review and meta-analysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Interstitial lung abnormalities in people with HIV infection and uninfected controls

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Bringing asthma care into the twenty-first century

    Research output: Contribution to journalReviewResearchpeer-review

  3. Usefulness of mannitol challenge testing for diagnosing asthma in everyday clinical practice

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Characteristics of patients with COVID-19 pneumonia at Hvidovre Hospital, March-April 2020

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: The most commonly applied treatment for acute exacerbations of chronic obstructive pulmonary disease (AECOPD) is a 5-day course of high-dose systemic corticosteroids. However, this treatment has not been shown to reduce mortality and can potentially have serious side effects. Recent research has shown that, presumably, only a subgroup of COPD patients identifieable by blood eosinophil count benefit from a rescue course of prednisolone. By applying a biomarker-guided strategy, the aim of this study is to determine whether it is possible to reduce the use of systemic corticosteroids in AECOPD without influencing the outcome.

METHODS: This is an ongoing prospective multicenter randomized controlled open label trial comprising 320 patients with AECOPD recruited from four hospitals in Denmark. The patients are randomized 1:1 to either standard care or eosinophil-guided corticosteroid-sparing therapy where prednisolone is not administered if the daily blood sampling reveals an eosinophil level below 0.3 × 10(9) cells/L. The primary endpoint is length of hospital stay within 14 days after recruitment. The secondary endpoints are treatment failure, 30-day mortality rate, COPD related re-admission rate, change in FEV1, and a number of adverse effect measures obtained within 3 months after the index hospitalisation date related to corticosteroid usage.

DISCUSSION: This will be a very large RCT providing knowledge about the effectiveness of individualized biomarker-guided corticosteroid therapy in hospitalised patients with AECOPD.

TRIAL REGISTRATION: Clinicaltrials.gov, NCT02857842 , 02-august-2016. Clinicaltrialregister.eu: Classification Code: 10,010,953, 02-marts-2016.

Original languageEnglish
JournalBMC Pulmonary Medicine
Volume17
Issue number1
Pages (from-to)e114
ISSN1471-2466
DOIs
Publication statusPublished - 15 Aug 2017

    Research areas

  • Journal Article

ID: 51631581